You are here
Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week.
Pooled data from SEC trials (FUTURE 2 and 3) assessed drug effects on enthesitis using the Leeds Enthesitis Index (LEI). Patients were assessed from baseline to week 104 along with other efficacy outcomes (ACR, PASI, HAQ-DI, SF-36 PCS, and DAS28-CRP).
Nearly two-thirs of 712 PsA patients had baseline enthesitis.
By week 16, full resolution was achieved in 65% (on 300 mg) and 56% (on 150 mg) versus 44% (on placebo).
At week 104, the improvement continued to rise with full resolution in 91% (300 mg) and 88% (150 mg).
The time to resolution of enthesitis was shorter with SEC (300 mg: 57days and 150 mg: 85 days) copared to 167 days on placebo.
Improvements in clinical efficacy outcomes were similar in patients with or without enthesitis treated with secukinumab 300 mg.
Secukinumab provided early and sustained resolution of enthesitis in patients with PsA over 2 years, with modestly better results using secukinumab 300 mg compared to the 150 mg dose.